Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$22.76 USD
+0.63 (2.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.76 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for Tyra Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -69.13 | -55.33 | -26.29 | -9.34 | NA |
Depreciation/Amortization & Depletion | 0.35 | 0.30 | 0.14 | 0.05 | NA |
Net Change from Assets/Liabilities | 6.36 | -5.85 | -0.48 | 1.07 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 12.28 | 10.59 | 2.89 | 0.46 | NA |
Net Cash From Operating Activities | -50.14 | -50.29 | -23.75 | -7.76 | NA |
Property & Equipment | -0.77 | -0.56 | -0.65 | -0.31 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -143.84 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -144.61 | -0.56 | -0.65 | -0.31 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.54 | 0.63 | 311.36 | 23.45 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.01 | -0.02 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | 1.54 | 0.63 | 311.35 | 23.43 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -193.21 | -50.21 | 286.96 | 15.36 | NA |
Cash at Beginning of Period | 252.21 | 302.43 | 15.47 | 0.11 | NA |
Cash at End of Period | 59.01 | 252.21 | 302.43 | 15.47 | NA |
Diluted Net EPS | -1.62 | -1.32 | -1.91 | NA | NA |
Fiscal Year End for Tyra Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -36.89 | -18.19 | -69.13 | -46.30 | -25.15 |
Depreciation/Amortization & Depletion | 0.25 | 0.12 | 0.35 | 0.25 | 0.17 |
Net Change from Assets/Liabilities | -1.07 | -6.84 | 6.36 | 0.10 | 0.56 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.43 | 2.89 | 12.28 | 9.34 | 4.97 |
Net Cash From Operating Activities | -32.29 | -22.03 | -50.14 | -36.61 | -19.46 |
Property & Equipment | -0.61 | 29.86 | -0.77 | -0.17 | -0.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -126.31 | -11.79 | -143.84 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -126.92 | 18.07 | -144.61 | -0.17 | -0.08 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 201.11 | 200.48 | 1.54 | 1.21 | 0.75 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.42 | -0.17 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 200.69 | 200.32 | 1.54 | 1.21 | 0.75 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 41.48 | 196.36 | -193.21 | -35.56 | -18.80 |
Cash at Beginning of Period | 59.01 | 59.01 | 252.21 | 252.21 | 252.21 |
Cash at End of Period | 100.49 | 255.37 | 59.01 | 216.65 | 233.41 |
Diluted Net EPS | -0.32 | -0.35 | -0.54 | -0.49 | -0.31 |